---
schema_version: "secwatch.filing_event.v1"
accession: "0000064803-23-000024"
form_type: "8-K"
ticker: "CVS"
cik: "0000064803"
company_name: "CVS HEALTH Corp"
filed_at: "2023-05-31T23:59:59+00:00"
generated_at: "2026-06-14T10:56:42.877504+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# CVS Health reaffirms FY2023 GAAP EPS $6.90-$7.12 and Adj. EPS $8.50-$8.70

## Summary
- Reaffirms full-year 2023 GAAP diluted EPS guidance range of $6.90 to $7.12.
- Reaffirms Adjusted EPS guidance range of $8.50 to $8.70 and cash flow from operations of $12.5B-$13.5B.
- Expects medical costs to remain in line with pricing; slightly >50% of earnings in H2 2023 with Q3 modestly higher than Q4.
- Guidance unchanged from prior announcement; no new financial results reported.

## SEC filing metadata
- accession: 0000064803-23-000024
- form_type: 8-K
- ticker: CVS
- cik: 0000064803
- company_name: CVS HEALTH Corp
- filed_at: 2023-05-31T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/64803/000006480323000024/0000064803-23-000024-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/64803/000006480323000024/cvs-20230531.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000064803-23-000024
- JSON: https://secwatch.observer/filing/0000064803-23-000024.json
- Plain text: https://secwatch.observer/filing/0000064803-23-000024.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.